12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 |
---|---|
ELISA | 0.305-5000 ng/ml |
Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Immobilized human CTLA-4 at 0.5 μg/ml (50 μL/well) can bind to Ipilimumab with a linear range of 0.305 ng/ml-5 μg/ml.